Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer

Overview of attention for article published in BMC Cancer, April 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
High Attention Score compared to outputs of the same age and source (96th percentile)

So far, Altmetric has seen 30 X posts from 23 X users, with an upper bound of 35,565 followers.

Today we are highlighting our DetermaIO publications in advanced non-small cell lung cancer: 1. Saltman, et al. https://t.co/Tw1aeqpDmf 2. Ranganath, et al. https://t.co/l4W5V9WCQ5 3. Nielsen, et al. https://t.co/6C3wIwTp1l #DetermaIO #LungCancer #NSCLC

RT @OncocyteCorp: DetermaIO™ high Advanced NSCLC Patients Were Significantly Associated with a 2X Better Progression Free Survival at One Y…

RT @OncocyteCorp: DetermaIO™ high Advanced NSCLC Patients Were Significantly Associated with a 2X Better Progression Free Survival at One Y…

RT @OncocyteCorp: DetermaIO™ high Advanced NSCLC Patients Were Significantly Associated with a 2X Better Progression Free Survival at One Y…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 26 additional X posts.